Table 2 Follow up of patients
No. | Age (years old) | Type | Surgical methods | Pathological type | Chemotherapy regimens | Follow-up |
|---|---|---|---|---|---|---|
1 | 36 | Localized | Tumor cytoreductive surgery | Epithelioid type | No chemotherapy | Survived 109 m after surgery without tumor recurrence |
2 | 47 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin) *2 | Died 21 m after surgery |
3 | 56 | Diffuse | Partial tumor resection | Epithelioid type | (Pemetrexed + Cisplatin) *3 | Died 19 m after surgery |
4 | 68 | Diffuse | Partial tumor resection | Epithelioid type | (Pemetrexed + Cisplatin) *5 | Died 33 m after surgery |
5 | 67 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin) *2 | Died 17 m after surgery |
6 | 70 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | Triplizumab *3 | Lost to follow-up |
7 | 69 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin) *6 | Survived, tumor recurrence |
8 | 65 | Diffuse | Partial tumor resection | Mixed | (Pemetrexed + Cisplatin) *4 | Died 22 m after surgery |
9 | 67 | Diffuse | Partial tumor resection | Epithelioid type | (Pemetrexed + Cisplatin + Bevacizumab) *3 | Survived, tumor recurrence |
10 | 27 | Localized | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin + Bevacizumab) *2 | Survived without tumor recurrence |